Selecting a First Dose With a MABEL Model

From Pharmacology to a First Dose

For a new biologic, the first-in-human dose should be informed by how little drug may be needed to produce a biological effect in people. A dose that appears small in mass units is not necessarily pharmacologically small: a high-affinity molecule may engage its target at very low concentrations, and downstream signaling can amplify that engagement. A minimum anticipated biological effect level (MABEL) approach starts with this pharmacology, estimates a concentration associated with a minimal effect, and then uses projected human pharmacokinetics (PK) to translate that concentration into a cautious starting dose.

MABEL is not a universal equation or a dose that guarantees no effect. It is an evidence-based estimate, assembled from relevant pharmacology such as receptor binding, target occupancy, and functional assays. The estimate depends on which data are reliable and how they relate to the intended clinical population. The worked case below is hypothetical; its calculations illustrate a decision process, not a dose recommendation for any actual product.

Definition: The minimum anticipated biological effect level (MABEL) is the estimated concentration or exposure at which a minimal biological effect is anticipated, based on relevant pharmacological evidence. A MABEL-based starting-dose calculation translates that estimate through a projected human exposure model and applies a justified margin for uncertainty. MABEL itself is not a guarantee of safety and is distinct from the dose ultimately selected for administration.

Estimate a Concentration From Receptor Occupancy

For a simple, reversible, one-to-one interaction at equilibrium, the fraction of receptors occupied by drug is approximated by the binding equation below. Here, \(C\) is the free drug concentration at the receptor and \(K_D\) is the equilibrium dissociation constant; both must use the same concentration units. This approximation assumes that free concentration is known, binding sites are sufficiently uniform, and the system is close to equilibrium. It may not describe tissue distribution, receptor internalization, or more complex binding behavior.

\theta = \frac{C}{K_D+C}

Solving for the concentration associated with a chosen occupancy fraction \(\theta\) gives the following relationship. It is a way to calculate a concentration marker, not a claim that a particular occupancy fraction is universally the threshold for a biological effect.

C = \frac{\theta}{1-\theta}K_D

Worked Example: Concentration at Ten Percent Occupancy

In a hypothetical binding study, a biologic has an estimated \(K_D\) of 0.20 nM. Calculate the free concentration associated with 10% receptor occupancy under the simple equilibrium model.

Set \(\theta=0.10\) and substitute \(K_D=0.20\) nM:

C = \frac{0.10}{1-0.10}(0.20\ \text{nM}) = \frac{0.10}{0.90}(0.20\ \text{nM}) = 0.0222\ \text{nM}

The model therefore associates 0.0222 nM free concentration with 10% occupancy. This calculation does not establish that 10% occupancy is harmless or that it is the first concentration with a biological effect. Receptor reserve, signaling amplification, and assay sensitivity can all make occupancy and functional response differ.

Combine Binding and Functional Evidence

A MABEL estimate should use the relevant pharmacology together rather than elevate one convenient result into a universal threshold. Binding affinity informs the concentration needed for target engagement. Functional assays test whether engagement produces a measurable response, and may reveal activity at lower concentrations than expected from a chosen occupancy marker. Assays using human cells and clinically relevant pathways are especially informative when they are well characterized and appropriate to the intended use.

For the hypothetical biologic, suppose the binding estimate is \(K_D=0.20\) nM, the team uses 10% occupancy as a conservative engagement marker, and a human-cell assay estimates an EC10 of 0.018 nM. Here, EC10 means the concentration estimated by the assay model to produce 10% of that assay's specified maximal response. The occupancy calculation gives 0.0222 nM; the functional assay gives 0.018 nM. Because the lower concentration is the more conservative estimate of minimal activity in this example, use 0.018 nM as the working MABEL concentration. This is a case-specific choice, not a rule that EC10 must always govern.

Selecting an endpoint requires judgment. An assay with a low apparent threshold is not automatically decisive if the response is noisy, the assay is poorly qualified, or the endpoint is not biologically relevant. Conversely, a weak signal should not be dismissed merely because it is inconvenient. The evidence and rationale for the selected concentration should be documented, including assay conditions, uncertainty in parameter estimates, and any plausible human-relevant effects that the assays do not measure.

Worked Example: Choosing the Governing MABEL Concentration

Use the hypothetical values above. The 10% occupancy concentration is 0.0222 nM, while the human-cell EC10 is 0.018 nM. Assume both results are sufficiently reliable and relevant for this teaching case.

Compare the two concentration estimates:

0.018\ \text{nM} < 0.0222\ \text{nM}

The lower estimate is the human-cell EC10, so the working MABEL concentration is 0.018 nM. At this concentration, predicted occupancy under the binding model is:

\theta = \frac{0.018}{0.20+0.018} = \frac{0.018}{0.218} = 0.0826

Thus, the predicted occupancy is about 8.26%. In this example, the assay's estimated minimal functional response occurs below the concentration associated with 10% occupancy. That difference is a reason to use the functional result in the integrated estimate; it is not evidence that occupancy and response must always follow this pattern.

Translate the MABEL Concentration Into a Dose

A concentration estimate becomes a dose only after specifying how a dose is expected to produce an early human concentration. For a transparent first calculation, suppose the hypothetical biologic is administered by a short intravenous infusion and the infusion is sufficiently brief that elimination during infusion is negligible. Assume a one-compartment approximation and a dose-proportional relationship at these low doses. Then the predicted end-of-infusion concentration is approximated by dose divided by central volume of distribution, \(V_c\). The concentration must be expressed as mass per volume to use this relationship.

These are simplifying assumptions, not established facts about a real biologic. A more complex model may be needed if distribution is not adequately represented by a single compartment, elimination during infusion matters, or dose proportionality fails at low concentrations. The concentration predicted by a PK model must also be comparable to the concentration used to define the MABEL; for example, free receptor-site concentration and total plasma concentration are not automatically interchangeable.

C_{\mathrm{end}} \approx \frac{\mathrm{Dose}}{V_c} \qquad\Longrightarrow\qquad \mathrm{Dose}_{\mathrm{MABEL}} \approx C_{\mathrm{MABEL}}V_c

For a hypothetical 150 kDa biologic, 1 nM corresponds to 0.15 mg/L: \(1\ \text{nM}\times150{,}000\ \text{g/mol}=0.15\ \text{g/m}^3=0.15\ \text{mg/L}\). This conversion assumes that the stated molecular mass adequately represents the molecular species used in the concentration measurements.

Worked Example: Convert the MABEL Concentration to a Dose

Use the working MABEL concentration of 0.018 nM. Assume a molecular mass of 150 kDa and a projected human \(V_c\) of 3.0 L. First convert concentration to mass per volume:

0.018\ \text{nM}\times0.15\ \frac{\text{mg/L}}{\text{nM}} =0.00270\ \text{mg/L}

Under the stated one-compartment, short-infusion approximation, the dose expected to produce this concentration is:

\mathrm{Dose}_{\mathrm{MABEL}} \approx 0.00270\ \text{mg/L}\times3.0\ \text{L} =0.00810\ \text{mg} =8.10\ \text{micrograms}

The result is a model-based dose associated with the estimated MABEL concentration before applying an additional safety margin. It is not yet the proposed starting dose. Its interpretation depends directly on the projected volume, the concentration conversion, and the assumed relationship between dose and early concentration.

Apply a Justified Margin and Check the Result

A safety factor can reduce the calculated dose to account for uncertainty in pharmacology, human PK projection, and the relationship between measured assay effects and clinical effects. There is no single factor that is appropriate for every biologic. Its size should reflect the quality and relevance of the evidence, the seriousness of plausible effects, and the consequences of being wrong. In this hypothetical case, suppose the team selects a 10-fold reduction as an explicitly illustrative margin.

\mathrm{Dose}_{\mathrm{start}} = \frac{\mathrm{Dose}_{\mathrm{MABEL}}}{10} = \frac{8.10\ \text{micrograms}}{10} = 0.810\ \text{micrograms}

A proposed starting dose of about 0.81 micrograms would, under the same linear concentration approximation, predict an early concentration one-tenth of the MABEL concentration: \(0.00180\) nM, or \(0.000270\) mg/L. The binding model then predicts occupancy of:

\theta = \frac{0.00180}{0.20+0.00180} =0.00892

That is about 0.892% occupancy under the stated model. This check shows the consequence of the 10-fold dose reduction within the simplified assumptions. It does not prove that the dose is safe: the model may be wrong, the functional response may be more sensitive than the estimate, and a small occupancy fraction is not a universal safety boundary.

Worked Example: Sensitivity to the Projected Central Volume

Suppose a plausible alternative human \(V_c\) is 2.0 L rather than 3.0 L, while the MABEL concentration and 10-fold margin remain unchanged. Recalculate the dose associated with the MABEL:

\mathrm{Dose}_{\mathrm{MABEL}} \approx 0.00270\ \text{mg/L}\times2.0\ \text{L} =0.00540\ \text{mg} =5.40\ \text{micrograms}

After the same illustrative margin, the starting dose is:

\mathrm{Dose}_{\mathrm{start}} = \frac{5.40\ \text{micrograms}}{10} =0.540\ \text{micrograms}

The dose decreases from 0.810 to 0.540 micrograms because, at a fixed dose, a smaller central volume predicts a higher concentration. This sensitivity check makes the role of the PK assumption visible. If plausible values of \(V_c\) produce materially different starting doses, the uncertainty should be addressed in the decision rather than hidden by reporting a single precise-looking number.

Assumptions, Diagnostics, and Limitations

Before relying on a MABEL-based dose, examine whether each link in the calculation is credible. Binding data should support the assumed interaction model and use an appropriate molecular species. Functional assays should be reproducible, sufficiently sensitive around the proposed concentration range, and relevant to human pharmacology. The PK projection should justify the concentration metric, distribution volume, route, infusion conditions, and dose proportionality used in the conversion.

Warning signs include inconsistent potency estimates across relevant human assays, a fitted EC10 that lies outside the measured concentration range, poor assay precision near the estimated threshold, or a large discrepancy between total and free concentrations. A receptor-occupancy model may also fail when ligand depletion is important, binding is cooperative, receptor levels vary substantially, or target engagement is not at equilibrium. If functional responses occur at concentrations below those supported by the binding model, investigate assay quality and mechanism rather than simply substituting the binding estimate.

The calculation also has scope limits. It does not capture every tissue concentration, time course, delayed response, or susceptible subgroup. A first dose is a decision under uncertainty, not the output of a formula alone. The selected margin and the assumptions behind it should be stated alongside the dose, and evidence that would prompt reassessment should be identified. A concentration-to-dose calculation can be useful and transparent while still being only one part of a broader first-in-human decision.

Common Pitfall: Treating Occupancy as an Effect Threshold

Incorrect reasoning: “The dose predicts less than 10% receptor occupancy, so it cannot cause a biological effect.” This conclusion does not follow from the occupancy calculation. A small fraction of occupied receptors may be enough to trigger a measurable response, particularly when signaling is amplified or the system has receptor reserve.

Correction: Treat occupancy as one line of evidence, then compare it with relevant functional pharmacology. In the worked case, the estimated functional EC10 of 0.018 nM is below the 0.0222 nM concentration associated with 10% occupancy, so it governs the integrated concentration estimate. Even that comparison is conditional on assay relevance and quality; it does not convert the EC10 into a guaranteed no-effect threshold.

Key takeaway: A MABEL-based first-dose estimate links pharmacological evidence to projected human exposure: estimate a conservative effect-related concentration, translate it using an explicit PK model, and apply a justified margin. The result is only as reliable as its assays, assumptions, and uncertainty assessment.

Check Your Understanding

Answer each question, then compare your reasoning with the solutions below.

For \(K_D=0.50\) nM, what free concentration corresponds to 5% occupancy under the simple equilibrium model?
A relevant functional assay estimates an EC10 of 0.012 nM, while a selected occupancy marker gives 0.020 nM. If both are reliable in a hypothetical case, which concentration is the more conservative working MABEL estimate, and why?
Using a molecular mass of 100 kDa, a MABEL concentration of 0.010 nM, and \(V_c=4.0\) L, calculate the dose associated with the MABEL before a safety factor.
Why does a predicted occupancy of 1% not establish that a first dose cannot produce a biological effect?

Solutions. For question 1, \(C=[0.05/(1-0.05)](0.50\ \text{nM})=0.0263\) nM. For question 2, use 0.012 nM as the more conservative estimate because it is below 0.020 nM and is assumed to be a reliable relevant functional result; the choice remains case-specific. For question 3, 100 kDa corresponds to 0.10 mg/L per nM, so the concentration is \(0.010\times0.10=0.00100\) mg/L. The dose is \(0.00100\ \text{mg/L}\times4.0\ \text{L}=0.00400\) mg, or 4.00 micrograms. For question 4, low occupancy can still produce a response through receptor reserve or signaling amplification, and the occupancy model may not capture the relevant biology. Functional evidence and uncertainty must also be considered.